4 Dividend Stocks Wall Street Gave Up On With Balance Sheets Built to Recover

Published November 20, 2026, 9:41am ET · 6 min read

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

UPS delivery truck driving along a street, side door open, UPS driver seated at the wheel, smiling toward the camera
© United Parcel Service Inc.

When a stock falls out of favor, the balance sheet decides what happens to your income. A company with manageable debt and steady cash flow can keep paying shareholders while it repairs the business. An overleveraged one cuts the dividend to survive (we laid out the seven warning signs that a big yield is about to be cut in a free guide here: Dividend Traps). The four names below have all been marked down by the market or by analysts, and all four have kept their payouts intact. T. Rowe Price Group (NASDAQ:TROW | TROW Price Prediction) shows how deep the pessimism runs. Its shares are down 36.94% over five years, even though the company carries no significant long-term debt.

Pfizer: Ultra-High Yield Backed by a Raised Outlook

Pfizer (NYSE:PFE) is the large-cap drugmaker behind Eliquis, Padcev and the Vyndaqel family. The market has turned against it. Shares trade at $27.69, down 28.51% over five years and 6.69% in the past month. Analysts are lukewarm: 17 rate it a hold, against 1 strong buy and 8 buys. The stock trades at a forward P/E of about 9.

Balance sheet read: Debt to equity is 0.78, net debt to EBITDA is 2.76, and interest coverage is 6.52x. Pfizer has made no share repurchases this year, leaving $3.3 billion[1] of authorization untouched while it keeps paying down debt. That ordering puts debt reduction and the dividend ahead of buybacks.

Yield and coverage: Pfizer yields 6.22%, which makes it the only ultra-high-yield name here. The annualized dividend of $1.72 works out to roughly 58% of the low end of raised adjusted EPS guidance of $2.95 to $3.05[2]. Cash coverage is tighter, since the free cash flow yield of 5.78% sits just below the dividend yield. First-half dividends totaled $4.9 billion[1].

Track record: The quarterly rate rose every year from $0.18 in 2010 to $0.42 in 2024 and has held at $0.43 since. The records also show the payout dropped from $0.32 to $0.16 in 2009, so the board has cut before.

Why the pessimism is overdone: Adjusted Q3 EPS of $0.87[2] beat the $0.728 estimate, and revenue guidance rose to $62.0 billion to $64.0 billion. Eliquis grew 25%[2] and Padcev 55%. This is a recovery and a poor fit for the value-trap label because the shrinkage is concentrated in COVID products like Paxlovid, down 63%[2], while the core portfolio grows.

Risk: Pfizer faces roughly $1.1 billion of generic and biosimilar headwinds this year, with the Eliquis patent expiration still ahead.

Bristol-Myers Squibb: A Single-Digit Multiple on a Growing Portfolio

Bristol-Myers Squibb (NYSE:BMY) sells oncology, cardiovascular and immunology drugs, including Opdivo, Eliquis and Camzyos. Even after a 34.43% gain over the past year, the market values it like a business in decline. Its forward P/E is about 9, and 17 analysts rate it a hold, compared with 4 strong buys and 6 buys. Shares slipped 5.41% in the past week to $58.95, and the stock underperformed competitors Wednesday.

Balance sheet read: Total debt of about $42.9 billion[3] is the heaviest load in this group. Liquidity offsets it: the CFO reported approximately $13 billion[4] in cash, equivalents and marketable securities, plus $4.2 billion of operating cash flow in the quarter. EBITDA stands at $18.24 billion.

Yield and coverage: The high-yield payout comes to 4.23%. The annualized $2.52 is about 40% of the low end of non-GAAP EPS guidance of $6.35 to $6.55[3], the widest earnings cushion here. Management reaffirmed its "commitment to the dividend."[4]

Track record: The records show no reduction in the quarterly rate going back to 1999. The rate has risen from $0.31 in 2009 to $0.63 this year.

Why the pessimism is overdone: The Growth Portfolio climbed 12% to $7.66 billion[3], and eight products[4] now annualize above $1 billion. A productivity program targets $2 billion[4] of efficiencies by the end of 2027. Bristol-Myers passes the value-trap test because new launches are already replacing lost revenue, and that shows up in reported sales.

Risk: Management expects a "$1.5 billion to $2 billion step-down in 2027"[4] tied to Eliquis. That comes on top of generic erosion that has already cut Revlimid sales 47%[3].

T. Rowe Price: A Debt-Free Payer Analysts Refuse to Like

T. Rowe Price manages mutual funds, ETFs and retirement accounts. No covering analyst rates it a buy or strong buy. 10 say hold, 1 says sell and 3 say strong sell. Shares trade at $105.98, about 11 times trailing earnings.

Balance sheet read: This is the cleanest balance sheet in the group. The firm holds $3.7743 billion[5] in cash against $11.37 billion of shareholders’ equity and discloses no significant long-term debt. Outflows can slow growth, but no lender can force a dividend decision.

Yield and coverage: T. Rowe Price offers a high yield of 4.71% on an annualized forward dividend of $5.20. Trailing dividends of $5.17 equal about 52% of trailing EPS of $9.88, and Q3 operating income rose 10.21%[5].

Track record: The regular quarterly payout has stepped higher every year in the records, from $0.34 in 2012 to $1.30 in 2026. Special payments of $1, $2 and $3 came on top in 2012, 2015 and 2021.

Why the pessimism is overdone: Average assets under management rose 9.5% to $1.887 trillion[5]. Multi-asset AUM grew 15.9% and alternatives grew 13.3%. Q3 adjusted EPS of $2.86[5] topped the $2.65 estimate. It escapes the value-trap label because growth in ETFs, SMAs and model portfolios gives it a path forward, and it has no debt to service while it builds them.

Risk: Clients pulled a net $28.3 billion[5] in Q3, and the fee rate slipped to 37.8 bps from 39.1 bps.

United Parcel Service: A Restructured Network With Cash to Spare

United Parcel Service (NYSE:UPS) runs the world’s largest package delivery network. Shares trade at $109.76, down 32.68% over five years. 12 analysts rate it a hold and 3 rate it a sell or strong sell, against 14 buys.

Balance sheet read: UPS ended Q3 with $6.8 billion[6] in cash and no commercial paper outstanding. It issued $1.3 billion[6] of debt to refinance a maturity and fund its pension, so the proceeds went to refinancing and pension funding.

Yield and coverage: UPS has a high yield of 5.91% on an annualized $6.56. Guidance calls for free cash flow of about $6.1 billion[7] against dividend payments of about $5.4 billion, a payout of roughly 89% of free cash flow. Coverage is thin but positive. The $1.4 billion[6] Driver Choice cash outlay ends in 2027. The CEO put it plainly: "our dividend is safe and secure."[6]

Track record: The quarterly payout rose every year from $0.91 in 2018 to $1.64 in 2025 and has held there through the latest declaration. The records show no cut.

Why the pessimism is overdone: U.S. Domestic operating margin widened to 7.0%[7] from 6.4%, and revenue per piece rose 6.1%. The Amazon volume reduction is complete, and transformation benefits are tracking toward nearly $3 billion[7]. That pairing of shrinking low-margin volume and rising margins is what a recovery looks like. A value trap would show volume and margins falling together.

Risk: Supply Chain Solutions adjusted operating profit fell 48.9%[7], alongside a $182 million goodwill impairment. If margin gains stall, the tight dividend coverage leaves little room.

How These Recovery Payers Compare

These four offer current income alongside a recovery that could take years to play out. T. Rowe Price brings the debt-free balance sheet, Bristol-Myers Squibb the widest earnings cushion, Pfizer the ultra-high yield, and UPS a cash-flow turnaround with an explicit dividend commitment from management. All four kept paying while the market lost interest, and the balance sheet figures above show each has the capacity to keep doing so.

Contact [email protected] for any questions or corrections.

Lee Jackson

Lee Jackson has covered Wall Street analysts' equity and debt research and equity strategy daily for 24/7 Wall St. since 2012. His broad, diverse career, including a stint as creative services director at an NBC affiliate in Austin, Texas, gives him unique insight into the financial industry.

Lee Jackson's journey in the financial industry spans more than 30 years, including nearly two decades as an institutional equity salesperson at Bear Stearns, Lehman Brothers, and Morgan Stanley. His career spanned pivotal sell-side Wall Street events, from the dot-com rise and bubble to the Long-Term Capital Management debacle, 9/11, and the Great Recession of 2008. This reflects his resilience and adaptability amid market volatility.

Lee Jackson’s practical financial industry experience, gained through a career at some of the biggest banks and brokerage firms, is complemented by a lifetime of writing across various platforms. This unique combination allows him to shed light on the intricacies of Wall Street in a way only someone with deep insider experience and knowledge can. Moreover, his extensive network across Wall Street continues to provide direct access for him and 24/7 Wall St., a privilege few firms enjoy.

Since 2012, Jackson’s work for 24/7 Wall St. has been featured in Barron’s, Yahoo Finance, MarketWatch, Business Insider, TradingView, Real Money, The Street, Seeking Alpha, Benzinga, and other media outlets. He attended the prestigious Cranbrook Schools in Bloomfield Hills, Michigan, and has a degree in broadcasting from the Specs Howard School of Media Arts.

All articles →

Sources

  1. Pfizer Form 8-K (Q2 FY2026)U.S. Securities and Exchange Commission
  2. Pfizer Form 8-K (Q3 FY2026)U.S. Securities and Exchange Commission
  3. Bristol-Myers Squibb Form 8-K (Q3 FY2026)U.S. Securities and Exchange Commission
  4. Bristol-Myers Squibb Company Q3 2026 earnings callBristol-Myers Squibb Company
  5. T. Rowe Price Form 8-K (Q3 FY2026)U.S. Securities and Exchange Commission
  6. United Parcel Service, Inc. Q3 2026 earnings callUnited Parcel Service, Inc.
  7. United Parcel Service Form 8-K (Q3 FY2026)U.S. Securities and Exchange Commission